ABSTRACT The interaction of the synthetic serum thymic factor (FTS, "facteur thymique serique") with human T lymphocytes from two established T The thymus gland has been shown to produce a number of factors or "hormones" that promote the differentiation of thymus-derived cells (T cells) and induce the appearance of their specific markers. We showed in 1971 that thymic extracts induce the appearance of the best-characterized of these markers, the 0 (Thy-i) antigen, on 0-negative bone marrow rosette-forming cells (1). It was ultimately demonstrated that there exists in normal serum an active principle with activity on rosette-forming cells identical to that of thymic extracts. The absence of this principle in serum from thymectomized or nude (athymic) mice demonstrated the strict thymic dependence of this factor (2).
ABSTRACT The interaction of the synthetic serum thymic factor (FTS, "facteur thymique serique") with human T lymphocytes from two established T cell lines (1301 and HSB2) was studied by using [3H]FTS. At 30'C, in the presence of 10 1301 and HSB2. These data indicate that only certain T cell subsets possess receptors with high affinity and specificity for FTS.
The thymus gland has been shown to produce a number of factors or "hormones" that promote the differentiation of thymus-derived cells (T cells) and induce the appearance of their specific markers. We showed in 1971 that thymic extracts induce the appearance of the best-characterized of these markers, the 0 (Thy-i) antigen, on 0-negative bone marrow rosette-forming cells (1) . It was ultimately demonstrated that there exists in normal serum an active principle with activity on rosette-forming cells identical to that of thymic extracts. The absence of this principle in serum from thymectomized or nude (athymic) mice demonstrated the strict thymic dependence of this factor (2) .
The molecule responsible for this activity has been isolated from pig serum and called "facteur thymique senique" (FTS). FTS is a nonapeptide whose amino acid sequence has been determined. FTS has been synthesized, and the synthetic material shows full biological activity and displays chromatographical characteristics identical to those of biological FTS in several chromatography systems (3, 4) .
The recent observation of the localization of antibodies directed against synthetic FTS on the thymic epithelium has provided direct demonstration of its thymic origin.t
The binding to specific receptors on its target cell is the first step in the action of a polypeptide hormone. It is thus of utmost importance for the understanding of the cellular mode of action of FTS to search for and characterize FTS receptors on lymphoid cells. With this in view, we have applied the methodology now well established for polypeptide hormones (5). This effort was significantly helped by the finding of two lymphoblastoid cell lines that showed high levels of FTS binding. 5 Ci/mmol (1 Ci = 3.7 X 1010 becquerels).
MATERIALS AND METHODS
Other Peptides. Several peptides were utilized for specificity studies. They included angiotensin II and ocytocin (Sigma), and human insulin and 125I-labeled insulin (Centre National de Transfusion Sanguine, Paris). Several FTS analogues (synthesized by E. Bricas and D. Blanot, Centre National de la Recherche Scientifique, Universit6 Paris Sud, Orsay, France) were also studied, including [D-Ala6]FTS (<Glu-Ala-Lys-Ser-GlnDAla-Gly-Ser-Asn), 2-9 octapeptide (Ala-Lys-Ser-Gln-GlyGly-Ser-Asn), and 3-9 heptapeptide (Lys-Ser-Gln-Gly-GlySer-Asn). Details of the synthesis of these analogues are described elsewhere (9) .
Binding Studies. Cultured lymphocytes (106 cells per ml) were incubated with [3H]FTS (10 nM) in medium containing 0.135 M NaCl, 0.05 M glucose, 0.05 M K2HPO4, 1 mM CaCl2, 0.05 M Tris, and 0.1% bovine serum albumin adjusted to pH 7.4 with Hepes. Bound and free radioactivity were separated by centrifugation at 12,000 X g. The supernatant was discarded Abbreviation: FTS, "facteur thymique serique" (serum thymic factor).
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The seven cell lines under study may be classified as T cells, B cells, or null cells according to the presence of B and T cell markers, immunoglobulin-specific membrane antigens, and certain enzymes (7, 8) . +, Positive; -, negative; H, high; L, low; ND, not determined; EAIgM, receptors for the Fc fragment of IgM; EAIgG, receptors for the Fc fragment of IgG; E, E rosettes; sIg, surface Ig; clg, cytoplasmic Ig; EAC, EAC rosettes; PNA, peanut agglutinin; cALL, common acute lymphoblastic leukemia; TDT, terminal deoxynucleotidyl transferase; ADA, adenosine deaminase.
and cells were washed with chilled incubation medium. After a second centrifugation, the supernatant was discarded and the pellet was dissolved with Soluene (Packard). Specifically bound radioactivity was defined as the difference between radioactivity bound in the absence and in the presence of unlabeled peptide (10 ,uM (10 ,uM) . At the times indicated the reaction was stopped by centrifugation at 12,000 X g. incubation medium. Conversely, at 150C the binding was much slower and a steady state was not obtained after 6 hr of incubation. Subsequent studies were performed after 120-min incubation at 300C. At this temperature specific and nonspecific binding are proportional to cell concentration in the range of 0.1-1 X 106 cells per ml (Fig. 3) . For most experiments, the concentration of 1 X 106 cells per ml was used. The addition of unlabeled FTS (20 ,uM) 90 min after addition of [3H]FTS to the cells was followed by a prompt dissociation of the bound radioactivity: 60% of [3H]FTS bound to its specific receptors was dissociated within 30 min (Fig. 4) .
Degradation of [3HPJFT and FIS Receptors. The biological preparation that contains specific binding sites also contains systems capable of degrading the peptide and the receptor. We have collected several pieces of evidence in order to evaluate the degradation of the peptide, of the receptor, or of both. As far as the degradation of [3H]FTS was concerned, three separate approaches were considered: study of [3H]FTS rebinding to intact cells, reactivity in the radioimmunoassay, and behavior in thin-layer chromatography. Study of the rebinding of labeled hormone to receptors present on fresh lymphocytes showed that only 5% of labeled FTS was degraded after a 3-hr incubation at 300C with the cell line (Fig. 5) . No cubation in the FTS radioimmunoassay (Fig. 5) . Finally, the integrity of [3H]FTS was established in thin-layer chromatography (one spot, in each solvent system).
In order to determine whether the receptors were degraded, the cultured cells were preincubated at 30'C for 0-180 min prior to the addition of labeled FTS for standard incubation. Neither specific nor nonspecific binding was significantly altered by this preincubation. These results exclude the release of soluble receptors during the binding period.
Effect (Fig. 7) .
Specificity of Binding. Increasing amounts of unlabeled FTS were added to the 1301 cultured cells in the presence of a constant amount of labeled FTS (10 nM). A concentration of 10 ,uM unlabeled FTS inhibited 90% of the binding of [3H]FTS. Partial inhibition was obtained at lower concentrations (between 0.1 and 20 ,M) (Fig. 8) .
The capacity of the 1301 cell line to bind various peptides, related or not to FTS, was investigated with the methodology described above for FTS. Ocytocin and angiotensin (0.01-10 ,uM), two peptides unrelated to FTS but of similar size, did not show any significant displacement Qf [3H]FTS binding (Fig.  9 ). The 1301 cell line bound human insulin, as has been previously reported for the cell line IM9 (12) . Such insulin receptors were shown to be independent from FTS receptors because addition of unlabeled insulin inhibited the binding of 125I- The specificity of the cell receptors for FTS was further confirmed by experiments studying the inhibition of [3H]FTS binding by low concentrations of FTS analogues (heptapeptide and octapeptide or an analogue with a D amino acid inserted). Results presented in Fig. 9 show that minor changes in FTS sequence, which do not alter biological activity (13) Finally, our data demonstrate the presence of FTS-specific receptors on two T lymphocyte lines. Thus non-antigen-specific
